Is a generic version of Triumeq available?
Triumeq is a medication developed by ViiV Healthcare, a joint partnership between GlaxoSmithKline and PepsiCo's health division. It combines three antiretroviral medications: abacavir, dolutegravir, and lamivudine. Triumeq is primarily used to treat HIV-1 infection in adults and children (2 years of age and older) with no antiretroviral treatment history or those who have failed previous treatment. As Triumeq has several patents related to its unique combination of components [1], the availability of a generic version is a topic of interest.
When will the Triumeq patent expire?
The Triumeq patent situation is complex, with multiple patents expiring at different times. The original patent for Triumeq's dolutegravir component has already expired in the United States, allowing for generic versions of the individual component to be produced. However, ViiV Healthcare has a range of secondary patents related to Triumeq as a whole, which are not yet expired. According to DrugPatentWatch.com, the last of these secondary patents is scheduled to expire on October 2026 [2].
Is a generic version of Triumeq available in the market?
Although a generic version of Triumeq as a whole is not yet available, the market offers generic versions of its individual components, including abacavir [3] and dolutegravir [4]. These generic versions are made by multiple manufacturers and are available in many countries. However, the availability, pricing, and accessibility of these generic versions may vary depending on your location and the specific treatment regimen prescribed by your healthcare provider.
What are the implications for patients?
For patients who rely on Triumeq for their HIV treatment, the impending expiration of the patent will likely lead to increased competition in the market, potentially resulting in reduced prices and improved accessibility to the treatment. As the patent expires, generic manufacturers will be able to enter the market, offering similar treatments at lower prices. This could lead to significant savings for patients, especially those without adequate insurance coverage.
Sources:
[1] DrugPatentWatch.com, retrieved May 24th, 2026
[2] DrugPatentWatch.com, retrieved May 24th, 2026
[3] Abacavir generic available in the US
[4] Dolutegravir generic available in the US